Stockholm-based Eyedentity secures €1.3 million to detect deadly eye cancer earlier with AI
MedTech startup Eyedentity has closed its first oversubscribed investment round at €1.3 million (SEK 15 million) to support regulatory approval, further product development and the expansion of Eyedentity’s AI-powered diagnostics platform into opticians, eye clinics and hospitals. The round was led by Norrsken Launcher, with participation from the Karolinska Institutet Innovation and a group of…
Stockholm-based Eyedentity has secured €1.3 million in investment to enhance its AI-powered diagnostic platform for detecting eye cancer early. The funding round, led by Norrsken Launcher and supported by the Karolinska Institutet Innovation and angel investors, will be utilized for regulatory approval, product development, and expanding the platform into various healthcare settings.
Eyedentity's technology aims to analyze fundus images captured during standard eye exams to identify serious eye diseases, particularly uveal melanoma. By providing decision support for opticians, the startup hopes to reduce false-positive referrals by 90%, streamlining the referral process for specialist care and decreasing unnecessary anxiety.
The investment aligns with recent European funding trends for AI-enabled diagnostics and MedTech innovations, totaling nearly €70 million across multiple companies.
Written by urgent.news from EU-Startups's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
